ASCO 2019: Venetoclax in Myeloma Combinations with Dr. Mike Thompson

An Overview of Multiple Myeloma Key Abstracts at ASCO 2019Подробнее

Dr. Kumar on Venetoclax in Multiple MyelomaПодробнее

Luciano Costa: Evaluating a Venetoclax and Carfilzomib Combination in MyelomaПодробнее

Venetoclax in Relapsed/Refractory Myeloma: The BELLINI TrialПодробнее

Venetoclax with bortezomib and dexamethasone in relapsed/refractory multiple myelomaПодробнее

ASH 2018: Dara+Velcade+Dex with or without VenetoclaxПодробнее

Dr. Cowan on the Role of Venetoclax in Multiple MyelomaПодробнее

Venetoclax for multiple myeloma - mechanism of action and next stepsПодробнее

MM: venetoclax, carfilzomib and dexamethasoneПодробнее

Venetoclax and the future of treatment of multiple myelomaПодробнее

Dr. Costa on Triplet of Venetoclax, Carfilzomib, and Dexamethasone in Multiple MyelomaПодробнее

Dr. Shah on the Role of Venetoclax in Multiple MyelomaПодробнее

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with RR multiple myelomaПодробнее

Venetoclax Plus Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple MyelomaПодробнее

Copy of Dr. Abedin on the Role of Venetoclax Plus Obinutuzumab in CLLПодробнее

Dr. Morgan on the Role of Venetoclax in Treating Multiple MyelomaПодробнее

Luciano Costa | ASCO 2018 | Phase II study of venetoclax, carfilzomib and dexamethasone in RRMMПодробнее

BELLINI Trial; Venetoclax-Vd in Multiple MyelomaПодробнее

Promising outlooks for venetoclax combinations for MMПодробнее